Mar 31, 2021 / 03:00PM GMT
Anupam Rama - JPMorgan Chase & Co, Research Division - VP and Analyst
Welcome, everyone, to the 10th Annual and 2021 JPMorgan Napa Valley Biotech Forum.
Our next presenting company here is Kodiak. And presenting on behalf of the company, we have CEO, Victor Perlroth. (Operator Instructions)
Victor, if you want to introduce the broader team on the line here, we can get started.
Victor Perlroth - Kodiak Sciences Inc. - Chairman, MD, CEO & President
Yes. Well, I'm Victor Perlroth, I'm the CEO of Kodiak. Thanks a lot, Anupam. We're glad to be part of the conference. And then we also have Jason Ehrlich, our Chief Medical and Development Officer on the line as well. So we'll look forward to chatting with you for the 45 minutes.
Questions and Answers:
Anupam Rama - JPMorgan Chase & Co, Research Division - VP and AnalystYes. So related to the KSI-301 ongoing Phase III studies, with DAZZLE enrollment and wet AMD complete, how are you thinking about the enrollment curves of GLEAM, GLIMMER